Fatigue News and Research

RSS

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

7 Jul 2014

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Research shows colon cancer survivors are more likely to experience pain in back, abdomen

Researchers from the University of Granada have discovered that colon cancer survivors are more likely to suffer future lesions related with pain in the back and lower abdomen than healthy individuals of the same gender and age.

27 Jun 2014

DBS improves motor and non motor symptoms of patients with early Parkinson's disease

Deep brain stimulation (DBS) has become a well-recognized non-pharmacologic treatment that improves motor symptoms of patients with early and advanced Parkinson's disease.

26 Jun 2014

Researchers challenge traditional approaches to manage ABI-associated behavior

Individuals with brain injury and their families often struggle to accept the associated personality changes. The behavior of individuals with acquired brain injury (ABI) is typically associated with problems such as aggression, agitation, non-compliance, and depression. Treatment goals often focus on changing the individual's behavior, frequently using consequence-based procedures or medication. In the current issue of NeuroRehabilitation leading researchers challenge this approach and recommend moving emphasis from dysfunction to competence.

26 Jun 2014

Tips to protect children from summer bugs

Mike Gittelman, MD, Co-Director, Comprehensive Children's Injury Center and the experts at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe while playing outdoors this summer.

26 Jun 2014

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

26 Jun 2014

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014

Required dose of saline solutions can prevent common injuries in football players

Some of the most common injuries in football players are violent joint sprains and muscle strains in the legs, which are sometimes caused by anxiety and fatigue accumulated after several games in a few weeks.

25 Jun 2014

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.

25 Jun 2014

Fatigue News and Research

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Research shows colon cancer survivors are more likely to experience pain in back, abdomen

DBS improves motor and non motor symptoms of patients with early Parkinson's disease

Researchers challenge traditional approaches to manage ABI-associated behavior

Tips to protect children from summer bugs

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Required dose of saline solutions can prevent common injuries in football players

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Testosterone therapy may improve aerobic capacity in aging men

Osteoarthritis may be treated with stem cell mobilization therapy

Yoga exercise program developed for patients living with pulmonary hypertension

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News